Yarrow Bioscience (NASDAQ:YARW) Announces Quarterly Earnings Results

Yarrow Bioscience (NASDAQ:YARW) posted its quarterly earnings results on Thursday. The company reported ($2.14) earnings per share for the quarter, Zacks reports. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

Yarrow Bioscience Stock Performance

Shares of Yarrow Bioscience stock traded down $0.05 during trading on Thursday, reaching $42.72. The company’s stock had a trading volume of 13,552 shares, compared to its average volume of 11,479. Yarrow Bioscience has a 52 week low of $14.02 and a 52 week high of $46.95. The stock has a market cap of $28.62 million, a PE ratio of -2.25 and a beta of 1.96.

Analyst Ratings Changes

Several analysts recently commented on the stock. BTIG Research began coverage on shares of Yarrow Bioscience in a report on Monday, August 3rd. They set a “buy” rating and a $58.00 target price for the company. TD Cowen assumed coverage on shares of Yarrow Bioscience in a research report on Tuesday, July 28th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Yarrow Bioscience presently has an average rating of “Buy” and an average price target of $58.00.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.